|
US5776093A
(en)
*
|
1985-07-05 |
1998-07-07 |
Immunomedics, Inc. |
Method for imaging and treating organs and tissues
|
|
KR20020027311A
(ko)
*
|
1999-05-07 |
2002-04-13 |
제넨테크, 인크. |
Ｂ 세포 표면 마커에 결합하는 길항물질을 이용한자가면역 질환의 치료
|
|
US8383081B2
(en)
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
|
US8119101B2
(en)
|
1999-05-10 |
2012-02-21 |
The Ohio State University |
Anti-CD74 immunoconjugates and methods of use
|
|
US7829064B2
(en)
*
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
|
WO2000074718A1
(en)
*
|
1999-06-09 |
2000-12-14 |
Immunomedics, Inc. |
Immunotherapy of autoimmune disorders using antibodies which target b-cells
|
|
HK1047702A1
(zh)
*
|
1999-07-12 |
2003-03-07 |
Genentech Inc. |
用与cd20结合的拮抗剂阻断对外来抗原的免疫应答
|
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
|
US6451284B1
(en)
|
1999-08-11 |
2002-09-17 |
Idec Pharmaceuticals Corporation |
Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
|
|
PT1255558E
(pt)
*
|
2000-02-16 |
2006-11-30 |
Genentech Inc |
Anticorpos anti-april e células hibridoma
|
|
CA2411102A1
(en)
*
|
2000-06-20 |
2001-12-27 |
Idec Pharmaceutical Corporation |
Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
|
CN1592645A
(zh)
*
|
2000-09-18 |
2005-03-09 |
拜奥根Idec公司 |
使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
|
|
US7754208B2
(en)
*
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US20030133939A1
(en)
*
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
CA2455915C
(en)
*
|
2001-03-29 |
2013-05-14 |
Cytokine Pharmasciences, Inc. |
Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
|
|
US20100291102A1
(en)
*
|
2001-07-02 |
2010-11-18 |
Ice Biologics Limited |
Therapeutic Agent
|
|
AU2003202093B2
(en)
*
|
2001-07-02 |
2010-05-13 |
Aimsco Limited |
Treatment of MS with goat serum
|
|
KR20040019105A
(ko)
*
|
2001-08-03 |
2004-03-04 |
제넨테크, 인크. |
ＴＡＣＩｓ 및 ＢＲ3 폴리펩티드 및 이의 용도
|
|
ES2342929T3
(es)
|
2001-09-26 |
2010-07-19 |
The Government of the United States of America as represented by the Secretary of Health and Human |
Anticuerpos anti-cd22 con afinidad aumentada por las celulas leucemicas que expresan cd22.
|
|
US7273888B2
(en)
|
2001-11-16 |
2007-09-25 |
Als Therapy Development Foundation, Inc. |
Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis
|
|
US8287864B2
(en)
|
2002-02-14 |
2012-10-16 |
Immunomedics, Inc. |
Structural variants of antibodies for improved therapeutic characteristics
|
|
CN100522999C
(zh)
*
|
2002-02-14 |
2009-08-05 |
免疫医疗公司 |
抗cd20抗体及其融合蛋白和使用方法
|
|
CN1646161A
(zh)
|
2002-02-21 |
2005-07-27 |
杜克大学 |
自身免疫疾病的药剂和治疗方法
|
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
|
WO2003074567A2
(en)
|
2002-03-01 |
2003-09-12 |
Immunomedics, Inc. |
Internalizing anti-cd74 antibodies and methods of use
|
|
US20040018557A1
(en)
|
2002-03-01 |
2004-01-29 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
|
US20080260731A1
(en)
*
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
|
AU2012216518B2
(en)
*
|
2002-03-01 |
2014-12-18 |
Immunomedics, Inc. |
Internalizing Anti-CD74 Antibodies and Methods of Use
|
|
US8361464B2
(en)
|
2002-03-01 |
2013-01-29 |
Immunomedics, Inc. |
Anthracycline-Antibody Conjugates for Cancer Therapy
|
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
|
AU2015201433B2
(en)
*
|
2002-03-01 |
2017-01-12 |
Immunomedics, Inc. |
Internalizing anti-cd74 antibodies and methods of use
|
|
TWI438010B
(zh)
|
2002-05-02 |
2014-05-21 |
Wyeth Corp |
卡奇黴素（ｃａｌｉｃｈｅａｍｉｃｉｎ）衍生物-載體共軛物
|
|
AU2015246156B2
(en)
*
|
2002-05-02 |
2017-06-29 |
Wyeth Holdings Llc. |
Calicheamicin derivative-carrier conjugates
|
|
GB0210121D0
(en)
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
|
AU2003256836A1
(en)
*
|
2002-07-25 |
2004-02-16 |
Genentech, Inc. |
Taci antibodies and uses thereof
|
|
WO2004035607A2
(en)
|
2002-10-17 |
2004-04-29 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
|
US8420086B2
(en)
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
|
PT1572744E
(pt)
|
2002-12-16 |
2010-09-07 |
Genentech Inc |
Variantes de imunoglobulina e utilizações destas
|
|
US7534427B2
(en)
*
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
|
US20040202666A1
(en)
*
|
2003-01-24 |
2004-10-14 |
Immunomedics, Inc. |
Anti-cancer anthracycline drug-antibody conjugates
|
|
AU2011236095B2
(en)
*
|
2003-01-24 |
2013-08-01 |
Immunomedics, Inc. |
Anthracycline-antibody conjugates
|
|
EP1460088A1
(en)
*
|
2003-03-21 |
2004-09-22 |
Biotest AG |
Humanized anti-CD4 antibody with immunosuppressive properties
|
|
AU2007242919B8
(en)
*
|
2003-04-09 |
2011-11-10 |
F. Hoffmann-La Roche Ag |
Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
|
|
HRP20090325T1
(en)
|
2003-04-09 |
2009-07-31 |
Genentech |
Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
|
|
NZ543960A
(en)
*
|
2003-05-09 |
2008-11-28 |
Univ Duke |
CD20-specific antibodies and methods of employing same
|
|
US20050163775A1
(en)
*
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
|
EP2272868B1
(en)
|
2003-06-05 |
2015-03-04 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
|
EP1648512A4
(en)
|
2003-07-31 |
2009-01-21 |
Immunomedics Inc |
ANTI-CD19 ANTIBODIES
|
|
US8147832B2
(en)
*
|
2003-08-14 |
2012-04-03 |
Merck Patent Gmbh |
CD20-binding polypeptide compositions and methods
|
|
ZA200601218B
(en)
*
|
2003-08-29 |
2007-05-30 |
Genentech Inc |
Anti-CD20 therapy of ocular disorders
|
|
ME01775B
(me)
|
2003-11-05 |
2011-02-28 |
Glycart Biotechnology Ag |
Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
|
|
CN1918181A
(zh)
*
|
2003-12-19 |
2007-02-21 |
健泰科生物技术公司 |
移植排斥中cd20的检测
|
|
CA2549122A1
(en)
*
|
2003-12-19 |
2005-07-07 |
Genentech, Inc. |
Detection of cd20 in therapy of autoimmune diseases
|
|
US8883160B2
(en)
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
EP1740946B1
(en)
|
2004-04-20 |
2013-11-06 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
|
BRPI0510224A
(pt)
*
|
2004-05-05 |
2007-10-23 |
Genentech Inc |
métodos de prevenção de doença autoimunológica e artigo industrializado
|
|
MXPA06014065A
(es)
|
2004-06-01 |
2007-01-31 |
Genentech Inc |
Conjugados de droga-anticuerpo y metodos.
|
|
AU2005251764A1
(en)
*
|
2004-06-04 |
2005-12-22 |
Genentech, Inc. |
Method for treating lupus
|
|
EP1753455A2
(en)
|
2004-06-04 |
2007-02-21 |
Genentech, Inc. |
Method for treating multiple sclerosis
|
|
US20060062787A1
(en)
*
|
2004-07-22 |
2006-03-23 |
Genentech, Inc. |
Method for treating Sjogren's syndrome
|
|
BRPI0514068B8
(pt)
|
2004-08-04 |
2021-05-25 |
Applied Molecular Evolution Inc |
anticorpo anti-cd20, e, composição farmacêutica
|
|
SG165344A1
(en)
*
|
2004-10-05 |
2010-10-28 |
Genentech Inc |
Method for treating vasculitis
|
|
TW200630106A
(en)
*
|
2004-10-08 |
2006-09-01 |
Wyeth Corp |
Immunotherapy of autoimmune disorders
|
|
WO2006076651A2
(en)
*
|
2005-01-13 |
2006-07-20 |
Genentech, Inc. |
Treatment method
|
|
DOP2006000029A
(es)
*
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
|
|
WO2006089133A2
(en)
*
|
2005-02-15 |
2006-08-24 |
Duke University |
Anti-cd19 antibodies and uses in oncology
|
|
US8444973B2
(en)
|
2005-02-15 |
2013-05-21 |
Duke University |
Anti-CD19 antibodies and uses in B cell disorders
|
|
TW200714289A
(en)
*
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
|
EP3332808B1
(en)
|
2005-03-03 |
2020-09-09 |
Immunomedics Inc. |
Humanized l243 antibodies
|
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
AR053579A1
(es)
*
|
2005-04-15 |
2007-05-09 |
Genentech Inc |
Tratamiento de la enfermedad inflamatoria intestinal (eii)
|
|
CA2607475A1
(en)
*
|
2005-04-22 |
2006-11-02 |
Genentech, Inc. |
Method for treating dementia or alzheimer's disease with a cd20 antibody
|
|
PL1874821T3
(pl)
|
2005-04-26 |
2013-09-30 |
Trion Pharma Gmbh |
Kombinacja przeciwciał i glikokortykoidów do leczenia raka
|
|
AU2006244445B2
(en)
*
|
2005-05-05 |
2013-04-18 |
Duke University |
Anti-CD19 antibody therapy for autoimmune disease
|
|
CN101223448B
(zh)
*
|
2005-05-20 |
2012-01-18 |
健泰科生物技术公司 |
来自自身免疫病受试者的生物学样品的预处理
|
|
WO2006133450A2
(en)
*
|
2005-06-08 |
2006-12-14 |
Duke University |
Anti-cd19 antibody therapy for the transplantation
|
|
HUE026303T2
(hu)
|
2005-07-25 |
2016-06-28 |
Emergent Product Dev Seattle |
B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
|
|
BRPI0614183A2
(pt)
|
2005-07-25 |
2011-03-15 |
Trubion Pharmaceuticals Inc |
uso de dose única de moléculas de ligação especìficas para cd20
|
|
CA2615731A1
(en)
*
|
2005-07-29 |
2007-02-08 |
Amgen Inc. |
Formulations that inhibit protein aggregation
|
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
|
CA2629306A1
(en)
|
2005-11-23 |
2007-05-31 |
Genentech, Inc. |
Methods and compositions related to b cell assays
|
|
WO2007103470A2
(en)
*
|
2006-03-06 |
2007-09-13 |
Medimmune, Inc. |
Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
US8389688B2
(en)
|
2006-03-06 |
2013-03-05 |
Aeres Biomedical, Ltd. |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
CN105837690A
(zh)
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
ME01786B
(me)
*
|
2006-08-14 |
2014-09-20 |
Xencor Inc |
Optimizovana antitela usmerena na cd19
|
|
CN103694349A
(zh)
*
|
2006-09-08 |
2014-04-02 |
米迪缪尼有限公司 |
人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用
|
|
WO2008034071A2
(en)
|
2006-09-15 |
2008-03-20 |
The Johns Hopkins University |
Method of identifying patients suitable for high-dose cyclophosphamide treatment
|
|
WO2008034074A2
(en)
|
2006-09-15 |
2008-03-20 |
The Johns Hopkins University |
Cyclosphosphamide in combination with anti-idiotypic vaccines
|
|
WO2008034076A2
(en)
|
2006-09-15 |
2008-03-20 |
The Johns Hopkins University |
Cyclophosphamide in combination with immune therapeutics
|
|
WO2008156494A1
(en)
*
|
2006-11-03 |
2008-12-24 |
The Johns Hopkins University |
Use of high-dose oxazaphosphorine drugs in combination with monoclonal antibodies for treating immune disorders
|
|
CN103172743B
(zh)
*
|
2006-12-01 |
2015-04-08 |
梅达雷克斯有限责任公司 |
结合cd22的人抗体及其用途
|
|
WO2008098145A1
(en)
*
|
2007-02-07 |
2008-08-14 |
University Of Washington |
Methods for modulating antigen-specific b cell responses
|
|
WO2008141278A1
(en)
*
|
2007-05-11 |
2008-11-20 |
Centocor, Inc. |
Method for preparing antibody conjugates
|
|
WO2009009523A2
(en)
|
2007-07-09 |
2009-01-15 |
Genentech, Inc. |
Prevention of disulfide bond reduction during recombinant production of polypeptides
|
|
WO2009052293A1
(en)
|
2007-10-16 |
2009-04-23 |
Zymogenetics, Inc. |
Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
|
|
WO2009054556A1
(en)
*
|
2007-10-24 |
2009-04-30 |
Sang Yun Nam |
Method for preparation of therapeutic b cells against autoimmune diseases which are induced by autoimmune cytotoxicity
|
|
US9026372B2
(en)
|
2007-11-21 |
2015-05-05 |
Accentia Biopharmaceuticals, Inc. |
Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
|
|
EP2077281A1
(en)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
|
JP5468015B2
(ja)
|
2008-01-08 |
2014-04-09 |
アクセリア ファーマシューティカルズ |
抗菌ペプチド系に対する作動薬
|
|
WO2009105548A2
(en)
*
|
2008-02-19 |
2009-08-27 |
Children's Medical Center Corporation |
Methods for treating diabetes
|
|
US8475785B2
(en)
|
2008-03-03 |
2013-07-02 |
The University Of Miami |
Allogeneic cancer cell-based immunotherapy
|
|
KR20100135807A
(ko)
*
|
2008-03-13 |
2010-12-27 |
바이오테스트 아게 |
질병 치료제
|
|
CA2718184A1
(en)
*
|
2008-03-13 |
2009-10-08 |
Biotest Ag |
Agent for treating disease
|
|
JP5604311B2
(ja)
*
|
2008-03-13 |
2014-10-08 |
バイオテスト・アクチエンゲゼルシヤフト |
疾患治療剤
|
|
US8968720B2
(en)
|
2008-03-20 |
2015-03-03 |
University Of Miami |
Heat shock protein GP96 vaccination and methods of using same
|
|
AU2009234277B2
(en)
|
2008-04-11 |
2014-12-04 |
Aptevo Research And Development Llc |
CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
|
EP2318048B1
(en)
*
|
2008-07-21 |
2019-05-29 |
Immunomedics, Inc. |
Structural variants of antibodies for improved therapeutic characteristics
|
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
治療進展型多發性硬化症之方法
|
|
RU2531548C2
(ru)
*
|
2008-09-29 |
2014-10-20 |
Биотест Аг |
Композиция для лечения заболевания
|
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
|
HRP20230487T1
(hr)
|
2009-02-13 |
2023-07-21 |
Immunomedics, Inc. |
Imunokonjugati s unutarstaničnom vezom koja se može rascijepiti
|
|
SI2464725T2
(sl)
|
2009-08-11 |
2025-06-30 |
F. Hoffmann-La Roche Ag |
Proizvodnja beljakovin v medijih za celične kulture brez glutamina
|
|
MX353186B
(es)
*
|
2009-09-03 |
2018-01-05 |
Genentech Inc |
Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
|
|
CN102482701B
(zh)
|
2009-09-16 |
2015-05-13 |
免疫医疗公司 |
I类抗-cea抗体及其使用
|
|
US20110070227A1
(en)
*
|
2009-09-18 |
2011-03-24 |
Anna-Marie Novotney-Barry |
Treatment of Autoimmune and Inflammatory Diseases
|
|
GB0917054D0
(en)
*
|
2009-09-29 |
2009-11-11 |
Cytoguide As |
Agents, uses and methods
|
|
GB0920944D0
(en)
|
2009-11-30 |
2010-01-13 |
Biotest Ag |
Agents for treating disease
|
|
CA2782194C
(en)
|
2009-12-02 |
2018-01-16 |
Immunomedics, Inc. |
Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
|
|
AU2011203890B2
(en)
*
|
2010-01-11 |
2013-05-30 |
Center For Molecular Medicine And Immunology |
Enhanced cytotoxicity of anti-CD74 and anti-HLA-DR antibodies with interferon-gamma
|
|
US9173961B2
(en)
|
2010-02-10 |
2015-11-03 |
Immunogen, Inc. |
CD20 antibodies and uses thereof
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP3431485B2
(en)
|
2010-10-01 |
2024-09-04 |
ModernaTX, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
CN102586408B
(zh)
*
|
2011-01-12 |
2015-08-19 |
首都医科大学附属北京安贞医院 |
高血压易感基因Mfn2单核苷酸多态性位点rs3820189的检测方法及检测试剂盒
|
|
CN103502472B
(zh)
|
2011-02-28 |
2017-06-06 |
弗·哈夫曼-拉罗切有限公司 |
生物标记物和用于预测对b‑细胞拮抗剂的响应的方法
|
|
WO2012135805A2
(en)
|
2011-03-31 |
2012-10-04 |
modeRNA Therapeutics |
Delivery and formulation of engineered nucleic acids
|
|
JP6024025B2
(ja)
|
2011-05-02 |
2016-11-09 |
イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． |
少容量投与用のアロタイプ選択抗体の限外濾過濃縮
|
|
EP2734228A4
(en)
|
2011-07-18 |
2015-04-08 |
Ohio State Innovation Foundation |
FTY720 INCREASES CD74 RECEPTOR EXPRESSION AND SENSITIZES CANCER CELLS TO CELL DEATH INDUCED BY ANTI-CD74 ANTIBODIES
|
|
HUE058855T2
(hu)
|
2011-08-16 |
2022-09-28 |
Morphosys Ag |
Kombinációs terápia, CD19 elleni ellenanyag és purinanalóg alkalmazásával
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2763701B1
(en)
|
2011-10-03 |
2018-12-19 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
MX2014004516A
(es)
|
2011-10-11 |
2015-01-16 |
Brigham & Womens Hospital |
Micro-arns en trastornos neurodegenerativos.
|
|
US9790280B2
(en)
|
2011-10-26 |
2017-10-17 |
Elanco Tiergesundheit Ag |
Monoclonal canine CD20 antibodies and methods of use
|
|
EP2788020A4
(en)
|
2011-12-05 |
2015-04-29 |
Immunomedics Inc |
THERAPEUTIC USE OF ANTI-CD22 ANTIBODIES FOR THE INDUCTION OF TROGO CYTOSIS
|
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
|
KR20140102759A
(ko)
|
2011-12-16 |
2014-08-22 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
DE18200782T1
(de)
|
2012-04-02 |
2021-10-21 |
Modernatx, Inc. |
Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
|
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
|
KR101482237B1
(ko)
*
|
2012-05-11 |
2015-01-14 |
가톨릭대학교 산학협력단 |
항 ｉｌ-６ｒ 및 ｔｎｆｒ２을 포함하는 이중특이적 단백질을 발현하는 미니서클 벡터를 포함하는 자가 면역 질환 치료용 약학 조성물
|
|
KR102165464B1
(ko)
|
2012-07-19 |
2020-10-14 |
레드우드 바이오사이언스 인코포레이티드 |
Cd22에 대해 특이적인 항체 및 이들의 사용 방법
|
|
AU2013302696B9
(en)
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
CA2892529C
(en)
|
2012-11-26 |
2023-04-25 |
Moderna Therapeutics, Inc. |
Terminally modified rna
|
|
US20240139324A1
(en)
|
2012-12-13 |
2024-05-02 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
|
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
|
US12310958B2
(en)
|
2012-12-13 |
2025-05-27 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
PL2900277T3
(pl)
|
2012-12-13 |
2022-05-16 |
Immunomedics, Inc. |
Dawkowanie immunokoniugatów przeciwciał i sn-38 dla poprawy skuteczności i zmniejszenia toksyczności
|
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
|
ES2819573T3
(es)
|
2012-12-13 |
2021-04-16 |
Immunomedics Inc |
Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
|
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
|
AU2014214843A1
(en)
|
2013-02-07 |
2015-05-21 |
Immunomedics, Inc. |
Pro-drug form (P2PDox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
|
|
EP2774930A1
(en)
|
2013-03-07 |
2014-09-10 |
Aptenia S.R.L. |
Metallocene compounds and labeled molecules comprising the same for in vivo imaging.
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
EA201690675A1
(ru)
|
2013-10-03 |
2016-08-31 |
Модерна Терапьютикс, Инк. |
Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
|
|
JP6447933B2
(ja)
|
2014-02-21 |
2019-01-09 |
アイビーシー ファーマスーティカルズ，インコーポレイテッド |
Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
|
|
US9139649B2
(en)
|
2014-02-25 |
2015-09-22 |
Immunomedics, Inc. |
Humanized anti-CD22 antibody
|
|
CA2944647C
(en)
|
2014-04-03 |
2025-07-08 |
Igm Biosciences Inc |
MODIFIED J STRING
|
|
WO2015200260A1
(en)
|
2014-06-24 |
2015-12-30 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
EP2990416B1
(en)
|
2014-08-29 |
2018-06-20 |
GEMoaB Monoclonals GmbH |
Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
|
JP7080055B2
(ja)
|
2014-09-08 |
2022-06-03 |
ルタナ ゲーエムベーハー |
細胞の細胞質への分子の送達のための構築物
|
|
AU2015328370B2
(en)
|
2014-10-07 |
2021-08-05 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
|
IL297997A
(en)
|
2015-03-04 |
2023-01-01 |
Igm Biosciences Inc |
Cd20 binding molecules and uses thereof
|
|
CA2981543A1
(en)
|
2015-04-22 |
2016-10-27 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
|
MX2017015493A
(es)
|
2015-05-30 |
2018-02-09 |
Molecular Templates Inc |
Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden.
|
|
IL302486A
(en)
|
2015-06-24 |
2023-06-01 |
Hoffmann La Roche |
Antibodies against the transnephrine receptor with adapted affinity
|
|
PT3313443T
(pt)
|
2015-06-25 |
2023-08-30 |
Immunomedics Inc |
Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
|
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
|
PL3316885T3
(pl)
|
2015-07-01 |
2021-12-06 |
Immunomedics, Inc. |
Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
|
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
|
HUE069387T2
(hu)
|
2015-09-30 |
2025-03-28 |
Igm Biosciences Inc |
Módosított J-lánccal rendelkezõ kötõmolekulák
|
|
US11639389B2
(en)
|
2015-09-30 |
2023-05-02 |
Igm Biosciences, Inc. |
Binding molecules with modified J-chain
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
JP6657392B2
(ja)
|
2015-10-02 |
2020-03-04 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗ヒトｃｄ２０／ヒトトランスフェリン受容体抗体及び使用方法
|
|
EP3373937B1
(en)
|
2015-11-09 |
2021-12-22 |
R.P. Scherer Technologies, LLC |
Anti-cd22 antibody-maytansine conjugates and methods of use thereof
|
|
US10865232B2
(en)
*
|
2015-11-13 |
2020-12-15 |
Dana-Farber Cancer Institute, Inc. |
NKG2D-IG fusion protein for cancer immunotherapy
|
|
EP3413914A4
(en)
|
2016-02-10 |
2019-10-16 |
Immunomedics, Inc. |
COMBINATION OF ABCG2 INHIBITORS WITH SACITUZUMAB GOVITECAN (IMMU-132) TO OVERCOME THE RESISTANCE TO SN-38 IN TROP-2-EXPRESSIVE CANCER
|
|
AU2017257254B2
(en)
|
2016-04-27 |
2022-02-24 |
Immunomedics, Inc. |
Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
|
|
GB2552774A
(en)
*
|
2016-07-12 |
2018-02-14 |
Evox Therapeutics Ltd |
EV-Mediated delivery of binding protein-small molecule conjugates
|
|
RU2758234C2
(ru)
|
2017-03-27 |
2021-10-26 |
Иммьюномедикс, Инк. |
ЛЕЧЕНИЕ ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ХАРАКТЕРИЗУЮЩЕГОСЯ ЭКСПРЕССИЕЙ Trop-2, С ПОМОЩЬЮ САЦИТУЗУМАБА ГОВИТЕКАНА И ИНГИБИТОРА Rad51
|
|
WO2018187074A1
(en)
|
2017-04-03 |
2018-10-11 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
|
CN108359004A
(zh)
*
|
2018-01-12 |
2018-08-03 |
中国农业科学院北京畜牧兽医研究所 |
犬重组干扰素-λ1及其制备方法与应用
|
|
CN116390772A
(zh)
|
2020-07-07 |
2023-07-04 |
博泰康医药公司 |
新型美登素类似物作为adc有效载荷及其在癌症治疗中的用途
|
|
WO2022008699A1
(en)
|
2020-07-09 |
2022-01-13 |
F. Hoffmann-La Roche Ag |
Concentrated compositions of proteins, their preparation and use thereof
|
|
US20250073349A1
(en)
|
2021-05-10 |
2025-03-06 |
Kawasaki Institute Of Industrial Promotion |
Antibody having reduced binding affinity for antigen
|
|
CN113855792B
(zh)
*
|
2021-12-01 |
2022-03-01 |
上海惠盾因泰生物科技有限公司 |
重组hEGF-CRM197肿瘤治疗性疫苗配制剂
|
|
CN114778417B
(zh)
*
|
2022-04-29 |
2024-02-13 |
上海顿慧医疗科技发展有限公司 |
免疫检查点抑制剂相关不良反应风险预测的模型建立方法
|
|
IL318865A
(en)
|
2022-08-10 |
2025-04-01 |
Kowa Co |
New drug complex
|